Form 4 for CVKD Cadrenal Therapeutics, Inc.
Accepted 2026-06-10 20:26:15 ET · period of report 2026-06-08 · accession 0001213900-26-067484 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-06-10 20:26 | 2026-06-08+ | CVKD | Pham Quang X | COB, CEO, Interim CFO, Dir, 10% | S - Sale | $4.17 | -22.4K | 150.8K | -13% | -$93.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-08 | S | D | 5,893 | $4.38 | 167,331 | D | — | — | (F1) Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-06-09 | S | D | 12,992 | $4.06 | 154,339 | D | — | — | (F1) Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 through $4.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-06-10 | S | D | 3,500 | $4.21 | 150,839 | D | — | — | (F1) Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |